New Study Finds Link Between Gout and Migraine
Posted on January 23 2024,
A longitudinal study published in the Journal of Clinical Medicine examined the relationship between gout and the risk of developing migraine disease. Researchers analyzed data from 23,137 gout patients and 92,548 matched controls in South Korea over a 16-year period.
The study found that patients with gout had a 26% higher risk of subsequently being diagnosed with migraine compared to those without gout. This heightened risk was especially strong for migraine without aura rather than migraines with aura.
The increased likelihood of migraine remained consistent even after accounting for various demographic factors like age, sex, income, lifestyle habits, and other medical conditions. The association was evident in both males and females, across income levels, in both rural and urban areas, and for those under age 70.
The findings indicate gout may be an independent risk factor for future migraine occurrence. The researchers theorize that changes in metabolism associated with gout could contribute to migraine developing.
While the study only included Koreans over the age of 40, it highlights the interconnected nature of migraine and other comorbid conditions. More research is needed on the biological mechanisms linking these disorders, however.
Migraine, Menopause, and Hormonal Health
Migraine affects women three times more than men, and menopause does not always bring relief. Nearly half of women continue having migraine attacks after menopause. Learn what the research says...
Read MoreWed, Jan 14, 26
New Emergency Department Migraine Treatment Guidelines
The American Headache Society (AHS) has released its 2025 guideline update for the acute treatment of migraine in adults presenting to the emergency department. This update, published in Headache in...
Read MoreSun, Jan 04, 26
Long-Term Safety of Anti-CGRP Monoclonal Antibodies
A comprehensive meta-analysis of over 4,300 patients reveals that erenumab, galcanezumab, fremanezumab, and eptinezumab maintain good tolerability beyond 12 months. Only 3% of patients stopped treatment due to adverse events,...
Read More
